{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["angiogenesis", "cancer", "cell signaling", "formononetin", "preclinical models"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "31052435", "DateRevised": {"Year": "2020", "Month": "09", "Day": "30"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "05", "Day": "01"}], "Language": ["eng"], "ELocationID": ["611", "10.3390/cancers11050611"], "Journal": {"ISSN": "2072-6694", "JournalIssue": {"Volume": "11", "Issue": "5", "PubDate": {"Year": "2019", "Month": "May", "Day": "01"}}, "Title": "Cancers", "ISOAbbreviation": "Cancers (Basel)"}, "ArticleTitle": "Focus on Formononetin: Anticancer Potential and Molecular Targets.", "Abstract": {"AbstractText": ["Formononetin, an isoflavone, is extracted from various medicinal plants and herbs, including the red clover (<i>Trifolium pratense</i><i>)</i> and Chinese medicinal plant <i>Astragalus membranaceus.</i> Formononetin's antioxidant and neuroprotective effects underscore its therapeutic use against Alzheimer's disease. Formononetin has been under intense investigation for the past decade as strong evidence on promoting apoptosis and against proliferation suggests for its use as an anticancer agent against diverse cancers. These anticancer properties are observed in multiple cancer cell models, including breast, colorectal, and prostate cancer. Formononetin also attenuates metastasis and tumor growth in various in vivo studies. The beneficial effects exuded by formononetin can be attributed to its antiproliferative and cell cycle arrest inducing properties. Formononetin regulates various transcription factors and growth-factor-mediated oncogenic pathways, consequently alleviating the possible causes of chronic inflammation that are linked to cancer survival of neoplastic cells and their resistance against chemotherapy. As such, this review summarizes and critically analyzes current evidence on the potential of formononetin for therapy of various malignancies with special emphasis on molecular targets."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore. samantha.ong@u.nus.edu."}], "LastName": "Ong", "ForeName": "Samantha Kah Ling", "Initials": "SKL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore. phcsmk@nus.edu.sg."}], "LastName": "Shanmugam", "ForeName": "Muthu K", "Initials": "MK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore. phcfanl@nus.edu.sg."}], "LastName": "Fan", "ForeName": "Lu", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA. SFraser78637@med.lecom.edu."}], "LastName": "Fraser", "ForeName": "Sarah E", "Initials": "SE"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Stem Cell and Cancer Biology Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia. frank.arfuso@curtin.edu.au."}], "LastName": "Arfuso", "ForeName": "Frank", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Science in Korean Medicine, Kyung Hee University, 24 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea. ksahn@khu.ac.kr."}], "LastName": "Ahn", "ForeName": "Kwang Seok", "Initials": "KS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore. phcgs@nus.edu.sg."}], "LastName": "Sethi", "ForeName": "Gautam", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA. abishayee@lecom.edu."}], "LastName": "Bishayee", "ForeName": "Anupam", "Initials": "A"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Cancers (Basel)", "NlmUniqueID": "101526829", "ISSNLinking": "2072-6694"}, "CoiStatement": "The authors declare that they have no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Martin T.A., Ye L., Sanders A.J., Lane J., WG J. Metastatic Cancer Clinical Biological Perspectives. Landes Bioscience 2000\u20132013; Austin, TX, USA: 2013. Cancer invasion and metastasis: Molecular and cellular perspective.", "ArticleIdList": ["10.1002/ijc.31937"]}, {"Citation": "Cooper G.M. The Cell: A Molecular Approach. 2nd ed. Sinauer Associates; Sunderland, MA, USA: 2000. The development and causes of cancer."}, {"Citation": "Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Pineros M., Znaor A., Bray F. Estimating the global cancer incidence and mortality in 2018: Globocan sources and methods. Int. J. Cancer. 2018 doi: 10.1002/ijc.31937.", "ArticleIdList": ["10.1002/ijc.31937", "30350310"]}, {"Citation": "Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394\u2013424. doi: 10.3322/caac.21492.", "ArticleIdList": ["10.3322/caac.21492", "30207593"]}, {"Citation": "Shanmugam M.K., Kannaiyan R., Sethi G. Targeting cell signaling and apoptotic pathways by dietary agents: Role in the prevention and treatment of cancer. Nutr. Cancer. 2011;63:161\u2013173. doi: 10.1080/01635581.2011.523502.", "ArticleIdList": ["10.1080/01635581.2011.523502", "21294053"]}, {"Citation": "Clarke G., Johnston S., Corrie P., Kuhn I., Barclay S. Withdrawal of anticancer therapy in advanced disease: A systematic literature review. BMC Cancer. 2015;15:892. doi: 10.1186/s12885-015-1862-0.", "ArticleIdList": ["10.1186/s12885-015-1862-0", "PMC4641339", "26559912"]}, {"Citation": "Onakpoya I.J., Heneghan C.J., Aronson J.K. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature. BMC Med. 2016;14:10. doi: 10.1186/s12916-016-0553-2.", "ArticleIdList": ["10.1186/s12916-016-0553-2", "PMC4740994", "26843061"]}, {"Citation": "Pan H., Gray R., Braybrooke J., Davies C., Taylor C., McGale P., Peto R., Pritchard K.I., Bergh J., Dowsett M., et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 2017;377:1836\u20131846. doi: 10.1056/NEJMoa1701830.", "ArticleIdList": ["10.1056/NEJMoa1701830", "PMC5734609", "29117498"]}, {"Citation": "Demain A.L., Vaishnav P. Natural products for cancer chemotherapy. Microb. Biotechnol. 2011;4:687\u2013699. doi: 10.1111/j.1751-7915.2010.00221.x.", "ArticleIdList": ["10.1111/j.1751-7915.2010.00221.x", "PMC3815406", "21375717"]}, {"Citation": "Neill U.S. From branch to bedside: Youyou tu is awarded the 2011 lasker~debakey clinical medical research award for discovering artemisinin as a treatment for malaria. J. Clin. Investig. 2011;121:3768\u20133773. doi: 10.1172/JCI60887.", "ArticleIdList": ["10.1172/JCI60887", "PMC3195493", "22059236"]}, {"Citation": "Bishayee A., Sethi G. Bioactive natural products in cancer prevention and therapy: Progress and promise. Semin. Cancer Biol. 2016;40\u201341:1\u20133. doi: 10.1016/j.semcancer.2016.08.006.", "ArticleIdList": ["10.1016/j.semcancer.2016.08.006", "27565447"]}, {"Citation": "Newman D.J., Cragg G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012;75:311\u2013335. doi: 10.1021/np200906s.", "ArticleIdList": ["10.1021/np200906s", "PMC3721181", "22316239"]}, {"Citation": "Cragg G.M., Pezzuto J.M. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med. Princ. Pract. 2016;25:41\u201359. doi: 10.1159/000443404.", "ArticleIdList": ["10.1159/000443404", "PMC5588531", "26679767"]}, {"Citation": "Deorukhkar A., Krishnan S., Sethi G., Aggarwal B.B. Back to basics: How natural products can provide the basis for new therapeutics. Exp. Opin. Invest. Drugs. 2007;16:1753\u20131773. doi: 10.1517/13543784.16.11.1753.", "ArticleIdList": ["10.1517/13543784.16.11.1753", "17970636"]}, {"Citation": "Yang S.F., Weng C.J., Sethi G., Hu D.N. Natural bioactives and phytochemicals serve in cancer treatment and prevention. Evid. Based Complement. Altern. Med. 2013;2013:698190. doi: 10.1155/2013/698190.", "ArticleIdList": ["10.1155/2013/698190", "PMC3880702", "24454507"]}, {"Citation": "Tang C.H., Sethi G., Kuo P.L. Novel medicines and strategies in cancer treatment and prevention. BioMed. Res. Int. 2014;2014:474078. doi: 10.1155/2014/474078.", "ArticleIdList": ["10.1155/2014/474078", "PMC4058237", "24971330"]}, {"Citation": "Hsieh Y.S., Yang S.F., Sethi G., Hu D.N. Natural bioactives in cancer treatment and prevention. BioMed. Res. Int. 2015;2015:182835. doi: 10.1155/2015/182835.", "ArticleIdList": ["10.1155/2015/182835", "PMC4391150", "25883943"]}, {"Citation": "Yarla N.S., Bishayee A., Sethi G., Reddanna P., Kalle A.M., Dhananjaya B.L., Dowluru K.S., Chintala R., Duddukuri G.R. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Semin. Cancer Biol. 2016;40\u201341:48\u201381. doi: 10.1016/j.semcancer.2016.02.001.", "ArticleIdList": ["10.1016/j.semcancer.2016.02.001", "26853158"]}, {"Citation": "Hasanpourghadi M., Looi C.Y., Pandurangan A.K., Sethi G., Wong W.F., Mustafa M.R. Phytometabolites targeting the warburg effect in cancer cells: A mechanistic review. Curr. Drug Targets. 2017;18:1086\u20131094. doi: 10.2174/1389450117666160401124842.", "ArticleIdList": ["10.2174/1389450117666160401124842", "27033190"]}, {"Citation": "Shanmugam M.K., Warrier S., Kumar A.P., Sethi G., Arfuso F. Potential role of natural compounds as anti-angiogenic agents in cancer. Curr. Vasc. Pharmacol. 2017;15:503\u2013519. doi: 10.2174/1570161115666170713094319.", "ArticleIdList": ["10.2174/1570161115666170713094319", "28707601"]}, {"Citation": "Aggarwal B.B., Sethi G., Baladandayuthapani V., Krishnan S., Shishodia S. Targeting cell signaling pathways for drug discovery: An old lock needs a new key. J. Cell Biochem. 2007;102:580\u2013592. doi: 10.1002/jcb.21500.", "ArticleIdList": ["10.1002/jcb.21500", "17668425"]}, {"Citation": "Jung Y.Y., Hwang S.T., Sethi G., Fan L., Arfuso F., Ahn K.S. Potential anti-inflammatory and anti-cancer properties of farnesol. Molecules. 2018;23:2827. doi: 10.3390/molecules23112827.", "ArticleIdList": ["10.3390/molecules23112827", "PMC6278318", "30384444"]}, {"Citation": "Merarchi M., Sethi G., Fan L., Mishra S., Arfuso F., Ahn K.S. Molecular targets modulated by fangchinoline in tumor cells and preclinical models. Molecules. 2018;23:2538. doi: 10.3390/molecules23102538.", "ArticleIdList": ["10.3390/molecules23102538", "PMC6222742", "30301146"]}, {"Citation": "Sethi G., Shanmugam M.K., Warrier S., Merarchi M., Arfuso F., Kumar A.P., Bishayee A. Pro-apoptotic and anti-cancer properties of diosgenin: A comprehensive and critical review. Nutrients. 2018;10:645. doi: 10.3390/nu10050645.", "ArticleIdList": ["10.3390/nu10050645", "PMC5986524", "29783752"]}, {"Citation": "Ko J.H., Sethi G., Um J.Y., Shanmugam M.K., Arfuso F., Kumar A.P., Bishayee A., Ahn K.S. The role of resveratrol in cancer therapy. Int. J. Mol. Sci. 2017;18:2589. doi: 10.3390/ijms18122589.", "ArticleIdList": ["10.3390/ijms18122589", "PMC5751192", "29194365"]}, {"Citation": "Tewari D., Nabavi S.F., Nabavi S.M., Sureda A., Farooqi A.A., Atanasov A.G., Vacca R.A., Sethi G., Bishayee A. Targeting activator protein 1 signaling pathway by bioactive natural agents: Possible therapeutic strategy for cancer prevention and intervention. Pharmacol. Res. 2018;128:366\u2013375. doi: 10.1016/j.phrs.2017.09.014.", "ArticleIdList": ["10.1016/j.phrs.2017.09.014", "28951297"]}, {"Citation": "Shanmugam M.K., Lee J.H., Chai E.Z., Kanchi M.M., Kar S., Arfuso F., Dharmarajan A., Kumar A.P., Ramar P.S., Looi C.Y., et al. Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds. Semin. Cancer Biol. 2016;40\u201341:35\u201347. doi: 10.1016/j.semcancer.2016.03.005.", "ArticleIdList": ["10.1016/j.semcancer.2016.03.005", "27038646"]}, {"Citation": "Shanmugam M.K., Nguyen A.H., Kumar A.P., Tan B.K., Sethi G. Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer. Cancer Lett. 2012;320:158\u2013170. doi: 10.1016/j.canlet.2012.02.037.", "ArticleIdList": ["10.1016/j.canlet.2012.02.037", "22406826"]}, {"Citation": "Shrimali D., Shanmugam M.K., Kumar A.P., Zhang J., Tan B.K., Ahn K.S., Sethi G. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 2013;341:139\u2013149. doi: 10.1016/j.canlet.2013.08.023.", "ArticleIdList": ["10.1016/j.canlet.2013.08.023", "23962559"]}, {"Citation": "Ranaware A.M., Banik K., Deshpande V., Padmavathi G., Roy N.K., Sethi G., Fan L., Kumar A.P., Kunnumakkara A.B. Magnolol: A neolignan from the magnolia family for the prevention and treatment of cancer. Int. J. Mol. Sci. 2018;19:2362. doi: 10.3390/ijms19082362.", "ArticleIdList": ["10.3390/ijms19082362", "PMC6121321", "30103472"]}, {"Citation": "Ko J.H., Arfuso F., Sethi G., Ahn K.S. Pharmacological utilization of bergamottin, derived from grapefruits, in cancer prevention and therapy. Int. J. Mol. Sci. 2018;19:4048. doi: 10.3390/ijms19124048.", "ArticleIdList": ["10.3390/ijms19124048", "PMC6321104", "30558157"]}, {"Citation": "Parikh N.R., Mandal A., Bhatia D., Siveen K.S., Sethi G., Bishayee A. Oleanane triterpenoids in the prevention and therapy of breast cancer: Current evidence and future perspectives. Phytochem. Rev. 2014;13:793\u2013810. doi: 10.1007/s11101-014-9337-5.", "ArticleIdList": ["10.1007/s11101-014-9337-5", "PMC4225818", "25395898"]}, {"Citation": "Shanmugam M.K., Dai X., Kumar A.P., Tan B.K., Sethi G., Bishayee A. Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: Preclinical and clinical evidence. Cancer Lett. 2014;346:206\u2013216. doi: 10.1016/j.canlet.2014.01.016.", "ArticleIdList": ["10.1016/j.canlet.2014.01.016", "PMC4004441", "24486850"]}, {"Citation": "Rajendran P., Li F., Shanmugam M.K., Kannaiyan R., Goh J.N., Wong K.F., Wang W., Khin E., Tergaonkar V., Kumar A.P., et al. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of stat3/jak2 signaling cascade in vitro and in vivo. Cancer Prev. Res. (Phila.) 2012;5:631\u2013643. doi: 10.1158/1940-6207.CAPR-11-0420.", "ArticleIdList": ["10.1158/1940-6207.CAPR-11-0420", "22369852"]}, {"Citation": "Kannaiyan R., Hay H.S., Rajendran P., Li F., Shanmugam M.K., Vali S., Abbasi T., Kapoor S., Sharma A., Kumar A.P., et al. Celastrol inhibits proliferation and induces chemosensitization through down-regulation of nf-kappab and stat3 regulated gene products in multiple myeloma cells. Br. J. Pharmacol. 2011;164:1506\u20131521. doi: 10.1111/j.1476-5381.2011.01449.x.", "ArticleIdList": ["10.1111/j.1476-5381.2011.01449.x", "PMC3221104", "21506956"]}, {"Citation": "Akincilar S.C., Low K.C., Liu C.Y., Yan T.D., Oji A., Ikawa M., Li S., Tergaonkar V. Quantitative assessment of telomerase components in cancer cell lines. FEBS Lett. 2015;589:974\u2013984. doi: 10.1016/j.febslet.2015.02.035.", "ArticleIdList": ["10.1016/j.febslet.2015.02.035", "25749370"]}, {"Citation": "Auyeung K.K., Ko J.K. Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell. Invest. New Drugs. 2010;28:1\u201313. doi: 10.1007/s10637-008-9207-3.", "ArticleIdList": ["10.1007/s10637-008-9207-3", "19139819"]}, {"Citation": "Sethi G., Shanmugam M.K., Ramachandran L., Kumar A.P., Tergaonkar V. Multifaceted link between cancer and inflammation. Biosci. Rep. 2012;32:1\u201315. doi: 10.1042/BSR20100136.", "ArticleIdList": ["10.1042/BSR20100136", "21981137"]}, {"Citation": "Liu D., Miao H., Zhao Y., Kang X., Shang S., Xiang W., Shi R., Hou A., Wang R., Zhao K., et al. NF-\u03baB potentiates tumor growth by suppressing a novel target lpts. Cell Commun. Signal. 2017;15:39. doi: 10.1186/s12964-017-0196-8.", "ArticleIdList": ["10.1186/s12964-017-0196-8", "PMC5634951", "29017500"]}, {"Citation": "Arora L., Kumar A.P., Arfuso F., Chng W.J., Sethi G. The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies. Cancers. 2018;10 doi: 10.3390/cancers10090327.", "ArticleIdList": ["10.3390/cancers10090327", "PMC6162647", "30217007"]}, {"Citation": "Lee J.H., Kim C., Lee S.G., Sethi G., Ahn K.S. Ophiopogonin d, a steroidal glycoside abrogates STAT3 signaling cascade and exhibits anti-cancer activity by causing GSH/GSSG imbalance in lung carcinoma. Cancers. 2018;10 doi: 10.3390/cancers10110427.", "ArticleIdList": ["10.3390/cancers10110427", "PMC6265752", "30413072"]}, {"Citation": "Wong A.L.A., Hirpara J.L., Pervaiz S., Eu J.Q., Sethi G., Goh B.C. Do stat3 inhibitors have potential in the future for cancer therapy? Expert Opin. Investig. Drugs. 2017;26:883\u2013887. doi: 10.1080/13543784.2017.1351941.", "ArticleIdList": ["10.1080/13543784.2017.1351941", "28714740"]}, {"Citation": "Lee J.H., Kim C., Baek S.H., Ko J.H., Lee S.G., Yang W.M., Um J.Y., Sethi G., Ahn K.S. Capsazepine inhibits jak/stat3 signaling, tumor growth, and cell survival in prostate cancer. Oncotarget. 2017;8:17700\u201317711. doi: 10.18632/oncotarget.10775.", "ArticleIdList": ["10.18632/oncotarget.10775", "PMC5392279", "27458171"]}, {"Citation": "Zhang J., Ahn K.S., Kim C., Shanmugam M.K., Siveen K.S., Arfuso F., Samym R.P., Deivasigamanim A., Lim L.H., Wang L., et al. Nimbolide-induced oxidative stress abrogates stat3 signaling cascade and inhibits tumor growth in transgenic adenocarcinoma of mouse prostate model. Antioxid. Redox Signal. 2016;24:575\u2013589. doi: 10.1089/ars.2015.6418.", "ArticleIdList": ["10.1089/ars.2015.6418", "26649526"]}, {"Citation": "Chai E.Z., Shanmugam M.K., Arfuso F., Dharmarajan A., Wang C., Kumar A.P., Samy R.P., Lim L.H., Wang L., Goh B.C., et al. Targeting transcription factor stat3 for cancer prevention and therapy. Pharmacol. Ther. 2016;162:86\u201397. doi: 10.1016/j.pharmthera.2015.10.004.", "ArticleIdList": ["10.1016/j.pharmthera.2015.10.004", "26478441"]}, {"Citation": "Subramaniam A., Shanmugam M.K., Ong T.H., Li F., Perumal E., Chen L., Vali S., Abbasi T., Kapoor S., Ahn K.S., et al. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of stat3. Br. J. Pharmacol. 2013;170:807\u2013821. doi: 10.1111/bph.12302.", "ArticleIdList": ["10.1111/bph.12302", "PMC3799595", "23848338"]}, {"Citation": "Subramaniam A., Shanmugam M.K., Perumal E., Li F., Nachiyappan A., Dai X., Swamy S.N., Ahn K.S., Kumar A.P., Tan B.K., et al. Potential role of signal transducer and activator of transcription (stat)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim. Biophys. Acta. 2013;1835:46\u201360. doi: 10.1016/j.bbcan.2012.10.002.", "ArticleIdList": ["10.1016/j.bbcan.2012.10.002", "23103770"]}, {"Citation": "Jung Y.Y., Lee J.H., Nam D., Narula A.S., Namjoshi O.A., Blough B.E., Um J.Y., Sethi G., Ahn K.S. Anti-myeloma effects of icariin are mediated through the attenuation of jak/stat3-dependent signaling cascade. Front. Pharmacol. 2018;9:531. doi: 10.3389/fphar.2018.00531.", "ArticleIdList": ["10.3389/fphar.2018.00531", "PMC5989039", "29899697"]}, {"Citation": "Kim C., Lee S.G., Yang W.M., Arfuso F., Um J.Y., Kumar A.P., Bian J., Sethi G., Ahn K.S. Formononetin-induced oxidative stress abrogates the activation of stat3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model. Cancer Lett. 2018;431:123\u2013141. doi: 10.1016/j.canlet.2018.05.038.", "ArticleIdList": ["10.1016/j.canlet.2018.05.038", "29857127"]}, {"Citation": "Li F., Zhang J., Arfuso F., Chinnathambi A., Zayed M.E., Alharbi S.A., Kumar A.P., Ahn K.S., Sethi G. Nf-kappab in cancer therapy. Arch. Toxicol. 2015;89:711\u2013731. doi: 10.1007/s00204-015-1470-4.", "ArticleIdList": ["10.1007/s00204-015-1470-4", "25690730"]}, {"Citation": "Manu K.A., Shanmugam M.K., Ramachandran L., Li F., Fong C.W., Kumar A.P., Tan P., Sethi G. First evidence that gamma-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of nf-kappab pathway. Clin. Cancer Res. 2012;18:2220\u20132229. doi: 10.1158/1078-0432.CCR-11-2470.", "ArticleIdList": ["10.1158/1078-0432.CCR-11-2470", "22351692"]}, {"Citation": "Shanmugam M.K., Ahn K.S., Lee J.H., Kannaiyan R., Mustafa N., Manu K.A., Siveen K.S., Sethi G., Chng W.J., Kumar A.P. Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma. Front. Pharmacol. 2018;9:365. doi: 10.3389/fphar.2018.00365.", "ArticleIdList": ["10.3389/fphar.2018.00365", "PMC5943600", "29773987"]}, {"Citation": "Manu K.A., Shanmugam M.K., Ramachandran L., Li F., Siveen K.S., Chinnathambi A., Zayed M.E., Alharbi S.A., Arfuso F., Kumar A.P., et al. Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of nf-kappab signaling cascade in gastric cancer. Cancer Lett. 2015;363:28\u201336. doi: 10.1016/j.canlet.2015.03.033.", "ArticleIdList": ["10.1016/j.canlet.2015.03.033", "25827070"]}, {"Citation": "Li F., Shanmugam M.K., Siveen K.S., Wang F., Ong T.H., Loo S.Y., Swamy M.M., Mandal S., Kumar A.P., Goh B.C., et al. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. Oncotarget. 2015;6:5147\u20135163. doi: 10.18632/oncotarget.2881.", "ArticleIdList": ["10.18632/oncotarget.2881", "PMC4467139", "25762616"]}, {"Citation": "Mohan C.D., Bharathkumar H., Dukanya , Rangappa S., Shanmugam M.K., Chinnathambi A., Alharbi S.A., Alahmadi T.A., Bhattacharjee A., Lobie P.E., et al. N-substituted pyrido-1,4-oxazin-3-ones induce apoptosis of hepatocellular carcinoma cells by targeting nf-kappab signaling pathway. Front. Pharmacol. 2018;9:1125.", "ArticleIdList": ["PMC6230568", "30455641"]}, {"Citation": "Raghunath A., Sundarraj K., Arfuso F., Sethi G., Perumal E. Dysregulation of NRF2 in hepatocellular carcinoma: Role in cancer progression and chemoresistance. Cancers. 2018;10 doi: 10.3390/cancers10120481.", "ArticleIdList": ["10.3390/cancers10120481", "PMC6315366", "30513925"]}, {"Citation": "Lee J.H., Kim C., Ko J.H., Jung Y.Y., Jung S.H., Kim E., Kong M., Chinnathambi A., Alahmadi T.A., Alharbi S.A., et al. Casticin inhibits growth and enhances ionizing radiation-induced apoptosis through the suppression of stat3 signaling cascade. J. Cell Biochem. 2019;120:9787\u20139798. doi: 10.1002/jcb.28259.", "ArticleIdList": ["10.1002/jcb.28259", "30520154"]}, {"Citation": "Shanmugam M.K., Ahn K.S., Hsu A., Woo C.C., Yuan Y., Tan K.H.B., Chinnathambi A., Alahmadi T.A., Alharbi S.A., Koh A.P.F., et al. Thymoquinone inhibits bone metastasis of breast cancer cells through abrogation of the cxcr4 signaling axis. Front. Pharmacol. 2018;9:1294. doi: 10.3389/fphar.2018.01294.", "ArticleIdList": ["10.3389/fphar.2018.01294", "PMC6288203", "30564115"]}, {"Citation": "Liu L., Ahn K.S., Shanmugam M.K., Wang H., Shen H., Arfuso F., Chinnathambi A., Alharbi S.A., Chang Y., Sethi G., et al. Oleuropein induces apoptosis via abrogating nf-kappab activation cascade in estrogen receptor-negative breast cancer cells. J. Cell Biochem. 2019;120:4504\u20134513. doi: 10.1002/jcb.27738.", "ArticleIdList": ["10.1002/jcb.27738", "30260018"]}, {"Citation": "Li F., Sethi G. Targeting transcription factor nf-kappab to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta. 2010;1805:167\u2013180.", "ArticleIdList": ["20079806"]}, {"Citation": "Sethi G., Tergaonkar V. Potential pharmacological control of the nf-kappab pathway. Trends. Pharmacol. Sci. 2009;30:313\u2013321. doi: 10.1016/j.tips.2009.03.004.", "ArticleIdList": ["10.1016/j.tips.2009.03.004", "19446347"]}, {"Citation": "Ahn K.S., Sethi G., Aggarwal B.B. Nuclear factor-kappa b: From clone to clinic. Curr. Mol. Med. 2007;7:619\u2013637. doi: 10.2174/156652407782564363.", "ArticleIdList": ["10.2174/156652407782564363", "18045141"]}, {"Citation": "Puar Y.R., Shanmugam M.K., Fan L., Arfuso F., Sethi G., Tergaonkar V. Evidence for the involvement of the master transcription factor nf-kappab in cancer initiation and progression. Biomedicines. 2018;6 doi: 10.3390/biomedicines6030082.", "ArticleIdList": ["10.3390/biomedicines6030082", "PMC6163404", "30060453"]}, {"Citation": "Chai E.Z., Siveen K.S., Shanmugam M.K., Arfuso F., Sethi G. Analysis of the intricate relationship between chronic inflammation and cancer. Biochem. J. 2015;468:1\u201315. doi: 10.1042/BJ20141337.", "ArticleIdList": ["10.1042/BJ20141337", "25940732"]}, {"Citation": "Loh C.Y., Arya A., Naema A.F., Wong W.F., Sethi G., Looi C.Y. Signal transducer and activator of transcription (stats) proteins in cancer and inflammation: Functions and therapeutic implication. Front. Oncol. 2019;9:48. doi: 10.3389/fonc.2019.00048.", "ArticleIdList": ["10.3389/fonc.2019.00048", "PMC6393348", "30847297"]}, {"Citation": "Lee M., Hirpara J.L., Eu J.Q., Sethi G., Wang L., Goh B.C., Wong A.L. Targeting stat3 and oxidative phosphorylation in oncogene-addicted tumors. Redox Biol. 2018:101073. doi: 10.1016/j.redox.2018.101073.", "ArticleIdList": ["10.1016/j.redox.2018.101073", "PMC6859582", "30594485"]}, {"Citation": "Liu Y., Tergaonkar V., Krishna S., Androphy E.J. Human papillomavirus type 16 e6-enhanced susceptibility of l929 cells to tumor necrosis factor alpha correlates with increased accumulation of reactive oxygen species. J. Biol. Chem. 1999;274:24819\u201324827. doi: 10.1074/jbc.274.35.24819.", "ArticleIdList": ["10.1074/jbc.274.35.24819", "10455154"]}, {"Citation": "Akincilar S.C., Khattar E., Boon P.L., Unal B., Fullwood M.J., Tergaonkar V. Long-range chromatin interactions drive mutant tert promoter activation. Cancer Discov. 2016;6:1276\u20131291. doi: 10.1158/2159-8290.CD-16-0177.", "ArticleIdList": ["10.1158/2159-8290.CD-16-0177", "27650951"]}, {"Citation": "Khattar E., Kumar P., Liu C.Y., Akincilar S.C., Raju A., Lakshmanan M., Maury J.J., Qiang Y., Li S., Tan E.Y., et al. Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting trna expression. J. Clin. Investig. 2016;126:4045\u20134060. doi: 10.1172/JCI86042.", "ArticleIdList": ["10.1172/JCI86042", "PMC5096818", "27643433"]}, {"Citation": "Mishra S., Verma S.S., Rai V., Awasthee N., Chava S., Hui K.M., Kumar A.P., Challagundla K.B., Sethi G., Gupta S.C. Long non-coding rnas are emerging targets of phytochemicals for cancer and other chronic diseases. Cell Mol. Life Sci. 2019;76:1947\u20131966. doi: 10.1007/s00018-019-03053-0.", "ArticleIdList": ["10.1007/s00018-019-03053-0", "PMC7775409", "30879091"]}, {"Citation": "Deng S., Shanmugam M.K., Kumar A.P., Yap C.T., Sethi G., Bishayee A. Targeting autophagy using natural compounds for cancer prevention and therapy. Cancer. 2019;125:1228\u20131246. doi: 10.1002/cncr.31978.", "ArticleIdList": ["10.1002/cncr.31978", "30748003"]}, {"Citation": "Siveen K.S., Sikka S., Surana R., Dai X., Zhang J., Kumar A.P., Tan B.K., Sethi G., Bishayee A. Targeting the stat3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim. Biophys. Acta. 2014;1845:136\u2013154. doi: 10.1016/j.bbcan.2013.12.005.", "ArticleIdList": ["10.1016/j.bbcan.2013.12.005", "24388873"]}, {"Citation": "Yang M.H., Jung S.H., Sethi G., Ahn K.S. Pleiotropic pharmacological actions of capsazepine, a synthetic analogue of capsaicin, against various cancers and inflammatory diseases. Molecules. 2019;24:995. doi: 10.3390/molecules24050995.", "ArticleIdList": ["10.3390/molecules24050995", "PMC6429077", "30871017"]}, {"Citation": "Girisa S., Shabnam B., Monisha J., Fan L., Halim C.E., Arfuso F., Ahn K.S., Sethi G., Kunnumakkara A.B. Potential of zerumbone as an anti-cancer agent. Molecules. 2019;24:734. doi: 10.3390/molecules24040734.", "ArticleIdList": ["10.3390/molecules24040734", "PMC6413012", "30781671"]}, {"Citation": "Lee J.H., Kim C., Um J.Y., Sethi G., Ahn K.S. Casticin-induced inhibition of cell growth and survival are mediated through the dual modulation of akt/mtor signaling cascade. Cancers. 2019;11:254. doi: 10.3390/cancers11020254.", "ArticleIdList": ["10.3390/cancers11020254", "PMC6406334", "30813295"]}, {"Citation": "Aggarwal V., Kashyap D., Sak K., Tuli H.S., Jain A., Chaudhary A., Garg V.K., Sethi G., Yerer M.B. Molecular mechanisms of action of tocotrienols in cancer: Recent trends and advancements. Int. J. Mol. Sci. 2019;20:656. doi: 10.3390/ijms20030656.", "ArticleIdList": ["10.3390/ijms20030656", "PMC6386883", "30717416"]}, {"Citation": "Polak R., Phillips E.M., Campbell A. Legumes: Health benefits and culinary approaches to increase intake. Clin. Diabetes. 2015;33:198\u2013205. doi: 10.2337/diaclin.33.4.198.", "ArticleIdList": ["10.2337/diaclin.33.4.198", "PMC4608274", "26487796"]}, {"Citation": "Cassileth B. Complementary therapies, herbs, and other otc agents: Red clover (trifolium pratense) Oncology (Williston Park) 2010;24:960.", "ArticleIdList": ["21138179"]}, {"Citation": "Kaczmarczyk-Sedlak I., Wojnar W., Zych M., Ozimina-Kaminska E., Taranowicz J., Siwek A. Effect of formononetin on mechanical properties and chemical composition of bones in rats with ovariectomy-induced osteoporosis. Evid. Based Complement. Altern. Med. 2013;2013:457052. doi: 10.1155/2013/457052.", "ArticleIdList": ["10.1155/2013/457052", "PMC3666393", "23762138"]}, {"Citation": "Patisaul H.B., Jefferson W. The pros and cons of phytoestrogens. Front Neuroendocrinol. 2010;31:400\u2013419. doi: 10.1016/j.yfrne.2010.03.003.", "ArticleIdList": ["10.1016/j.yfrne.2010.03.003", "PMC3074428", "20347861"]}, {"Citation": "Lukaczer D., Darland G., Tripp M., Liska D., Lerman R.H., Schiltz B., Bland J.S. Clinical effects of a proprietary combination isoflavone nutritional supplement in menopausal women: A pilot trial. Altern. Ther. Health Med. 2005;11:60\u201365.", "ArticleIdList": ["16189949"]}, {"Citation": "Hidalgo L.A., Chedraui P.A., Morocho N., Ross S., San Miguel G. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: A randomized, double-blind, placebo-controlled study. Gynecol. Endocrinol. 2005;21:257\u2013264. doi: 10.1080/09513590500361192.", "ArticleIdList": ["10.1080/09513590500361192", "16373244"]}, {"Citation": "Atkinson C., Compston J.E., Day N.E., Dowsett M., Bingham S.A. The effects of phytoestrogen isoflavones on bone density in women: A double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 2004;79:326\u2013333. doi: 10.1093/ajcn/79.2.326.", "ArticleIdList": ["10.1093/ajcn/79.2.326", "14749241"]}, {"Citation": "Nestel P.J., Pomeroy S., Kay S., Komesaroff P., Behrsing J., Cameron J.D., West L. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J. Clin. Endocrinol. Metab. 1999;84:895\u2013898. doi: 10.1210/jc.84.3.895.", "ArticleIdList": ["10.1210/jc.84.3.895", "10084567"]}, {"Citation": "Wang A.L., Li Y., Zhao Q., Fan L.Q. Formononetin inhibits colon carcinoma cell growth and invasion by microrna149mediated ephb3 downregulation and inhibition of pi3k/akt and stat3 signaling pathways. Mol. Med. Rep. 2018;17:7721\u20137729.", "ArticleIdList": ["PMC5983960", "29620230"]}, {"Citation": "Zhang S., Tang X., Tian J., Li C., Zhang G., Jiang W., Zhang Z. Cardioprotective effect of sulphonated formononetin on acute myocardial infarction in rats. Basic Clin. Pharmacol. Toxicol. 2011;108:390\u2013395. doi: 10.1111/j.1742-7843.2011.00676.x.", "ArticleIdList": ["10.1111/j.1742-7843.2011.00676.x", "21232020"]}, {"Citation": "Zhu H., Zou L., Tian J., Lin F., He J., Hou J. Protective effects of sulphonated formononetin in a rat model of cerebral ischemia and reperfusion injury. Planta Med. 2014;80:262\u2013268. doi: 10.1055/s-0033-1360340.", "ArticleIdList": ["10.1055/s-0033-1360340", "24549929"]}, {"Citation": "Tolleson W.H., Doerge D.R., Churchwell M.I., Marques M.M., Roberts D.W. Metabolism of biochanin a and formononetin by human liver microsomes in vitro. J. Agric. Food Chem. 2002;50:4783\u20134790. doi: 10.1021/jf025549r.", "ArticleIdList": ["10.1021/jf025549r", "12166960"]}, {"Citation": "Park J., Kim S.H., Cho D., Kim T.S. Formononetin, a phyto-oestrogen, and its metabolites up-regulate interleukin-4 production in activated t cells via increased ap-1 DNA binding activity. Immunology. 2005;116:71\u201381. doi: 10.1111/j.1365-2567.2005.02199.x.", "ArticleIdList": ["10.1111/j.1365-2567.2005.02199.x", "PMC1802402", "16108819"]}, {"Citation": "Liu Y., He J., Chen X., Li J., Shen M., Yu W., Yang Y., Xiao Z. The proapoptotic effect of formononetin in human osteosarcoma cells: Involvement of inactivation of erk and akt pathways. Cell Physiol. Biochem. 2014;34:637\u2013645. doi: 10.1159/000363029.", "ArticleIdList": ["10.1159/000363029", "25170541"]}, {"Citation": "Chen J., Zeng J., Xin M., Huang W., Chen X. Formononetin induces cell cycle arrest of human breast cancer cells via igf1/pi3k/akt pathways in vitro and in vivo. Horm. Metab. Res. 2011;43:681\u2013686. doi: 10.1055/s-0031-1286306.", "ArticleIdList": ["10.1055/s-0031-1286306", "21932171"]}, {"Citation": "Chen J., Sun L. Formononetin-induced apoptosis by activation of ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells. Horm. Metab. Res. 2012;44:943\u2013948. doi: 10.1055/s-0032-1321818.", "ArticleIdList": ["10.1055/s-0032-1321818", "22828872"]}, {"Citation": "Chen J., Zhao X., Ye Y., Wang Y., Tian J. Estrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin. Cell Physiol. Biochem. 2013;32:1790\u20131797. doi: 10.1159/000356612.", "ArticleIdList": ["10.1159/000356612", "24355881"]}, {"Citation": "Ye Y., Hou R., Chen J., Mo L., Zhang J., Huang Y., Mo Z. Formononetin-induced apoptosis of human prostate cancer cells through erk1/2 mitogen-activated protein kinase inactivation. Horm. Metab. Res. 2012;44:263\u2013267. doi: 10.1055/s-0032-1301922.", "ArticleIdList": ["10.1055/s-0032-1301922", "22328166"]}, {"Citation": "Li T., Zhao X., Mo Z., Huang W., Yan H., Ling Z., Ye Y. Formononetin promotes cell cycle arrest via downregulation of akt/cyclin d1/cdk4 in human prostate cancer cells. Cell Physiol. Biochem. 2014;34:1351\u20131358. doi: 10.1159/000366342.", "ArticleIdList": ["10.1159/000366342", "25301361"]}, {"Citation": "Yang Y., Zhao Y., Ai X., Cheng B., Lu S. Formononetin suppresses the proliferation of human non-small cell lung cancer through induction of cell cycle arrest and apoptosis. Int. J. Clin. Exp. Pathol. 2014;7:8453\u20138461.", "ArticleIdList": ["PMC4313991", "25674209"]}, {"Citation": "Jin Y.M., Xu T.M., Zhao Y.H., Wang Y.C., Cui M.H. In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HELA. Tumour Biol. 2014;35:2279\u20132284. doi: 10.1007/s13277-013-1302-1.", "ArticleIdList": ["10.1007/s13277-013-1302-1", "24272199"]}, {"Citation": "Wu Y., Zhang X., Li Z., Yan H., Qin J., Li T. Formononetin inhibits human bladder cancer cell proliferation and invasiveness via regulation of mir-21 and pten. Food Funct. 2017;8:1061\u20131066. doi: 10.1039/C6FO01535B.", "ArticleIdList": ["10.1039/C6FO01535B", "28139790"]}, {"Citation": "Park S., Bazer F.W., Lim W., Song G. The o-methylated isoflavone, formononetin, inhibits human ovarian cancer cell proliferation by sub g0/g1 cell phase arrest through PI3K/AKT and ERK1/2 inactivation. J. Cell Biochem. 2018;119:7377\u20137387. doi: 10.1002/jcb.27041.", "ArticleIdList": ["10.1002/jcb.27041", "29761845"]}, {"Citation": "Wu X.L., Li H.Y., Wang R.H., Ma X.X., Yue B., Yan J., Yang N.L., Xing X.H., Sheng Z.F., Wang G.H., et al. Formononetin suppresses hypoxia inducible factor-1\u03b1/inflammatory cytokines expression via inhibiting akt signal pathway in multiple myeloma cells. Int. J. Clin. Exp. Med. 2016;9:1117\u20131127."}, {"Citation": "Huang J., Xie M., Gao P., Ye Y., Liu Y., Zhao Y., Luo W., Ling Z., Cao Y., Zhang S., et al. Antiproliferative effects of formononetin on human colorectal cancer via suppressing cell growth in vitro and in vivo. Proc. Biochem. 2015;50:912\u2013917. doi: 10.1016/j.procbio.2015.03.001.", "ArticleIdList": ["10.1016/j.procbio.2015.03.001"]}, {"Citation": "Fouad Y.A., Aanei C. Revisiting the hallmarks of cancer. Am. J. Cancer Res. 2017;7:1016\u20131036.", "ArticleIdList": ["PMC5446472", "28560055"]}, {"Citation": "Aapro M.S., Plezia P.M., Alberts D.S., Graham V., Jones S.E., Surwit E.A., Moon T.E. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J. Clin. Oncol. 1984;2:466\u2013471. doi: 10.1200/JCO.1984.2.5.466.", "ArticleIdList": ["10.1200/JCO.1984.2.5.466", "6539363"]}, {"Citation": "Huang W.J., Bi L.Y., Li Z.Z., Zhang X., Ye Y. Formononetin induces the mitochondrial apoptosis pathway in prostate cancer cells via downregulation of the igf-1/igf-1r signaling pathway. Pharm. Biol. 2013;52:466\u2013470. doi: 10.3109/13880209.2013.842600.", "ArticleIdList": ["10.3109/13880209.2013.842600", "24359236"]}, {"Citation": "Hu W., Xiao Z. Formononetin induces apoptosis of human osteosarcoma cell line u2os by regulating the expression of bcl-2, bax and mir-375 in vitro and in vivo. Cell Physiol. Biochem. 2015;37:933\u2013939. doi: 10.1159/000430220.", "ArticleIdList": ["10.1159/000430220", "26381132"]}, {"Citation": "Liu X.J., Li Y.Q., Chen Q.Y., Xiao S.J., Zeng S.E. Up-regulating of rasd1 and apoptosis of du-145 human prostate cancer cells induced by formononetin in vitro. Asian Pac. J. Cancer Prev. 2014;15:2835\u20132839. doi: 10.7314/APJCP.2014.15.6.2835.", "ArticleIdList": ["10.7314/APJCP.2014.15.6.2835", "24761910"]}, {"Citation": "Zhang X., Bi L., Ye Y., Chen J. Formononetin induces apoptosis in pc-3 prostate cancer cells through enhancing the bax/bcl-2 ratios and regulating the p38/akt pathway. Nutr. Cancer. 2014;66:656\u2013661. doi: 10.1080/01635581.2014.894098.", "ArticleIdList": ["10.1080/01635581.2014.894098", "24666255"]}, {"Citation": "Zhou R., Xu L., Ye M., Liao M., Du H., Chen H. Formononetin inhibits migration and invasion of mda-mb-231 and 4t1 breast cancer cells by suppressing mmp-2 and mmp-9 through pi3k/akt signaling pathways. Horm. Metab. Res. 2014;46:753\u2013760. doi: 10.1055/s-0034-1376977.", "ArticleIdList": ["10.1055/s-0034-1376977", "24977660"]}, {"Citation": "Auyeung K.K., Law P.C., Ko J.K. Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft. Oncol. Rep. 2012;28:2188\u20132194. doi: 10.3892/or.2012.2056.", "ArticleIdList": ["10.3892/or.2012.2056", "23023137"]}, {"Citation": "Zhang X., Ni Q., Wang Y., Fan H., Li Y. Synergistic anticancer effects of formononetin and temozolomide on glioma c6 cells. Biol. Pharm. Bull. 2018;41:1194\u20131202. doi: 10.1248/bpb.b18-00002.", "ArticleIdList": ["10.1248/bpb.b18-00002", "29848900"]}, {"Citation": "Liu Q., Sun Y., Zheng J.M., Yan X.L., Chen H.M., Chen J.K., Huang H.Q. Formononetin sensitizes glioma cells to doxorubicin through preventing EMT via inhibition of histone deacetylase 5. Int. J. Clin. Exp. Pathol. 2015;8:6434\u20136441.", "ArticleIdList": ["PMC4525853", "26261519"]}, {"Citation": "Qi C., Xie M., Liang J., Li H., Li Z., Shi S., Yang X., Wang Z., Tang J., Tang A. Formononetin targets the mapk and pi3k/akt pathways to induce apoptosis in human nasopharyngeal carcinoma cells in vitro and in vivo. Int. J. Clin. Exp. Med. 2016;9:1180\u20131189."}, {"Citation": "Rosse T., Olivier R., Monney L., Rager M., Conus S., Fellay I., Jansen B., Borner C. Bcl-2 prolongs cell survival after bax-induced release of cytochrome c. Nature. 1998;391:496\u2013499. doi: 10.1038/35160.", "ArticleIdList": ["10.1038/35160", "9461218"]}, {"Citation": "Hu W., Wu X., Tang J., Xiao N., Zhao G., Zhang L., Ou L. In vitro and in vivo studies of antiosteosarcoma activities of formononetin. J. Cell. Physiol. 2019 doi: 10.1002/jcp.28349.", "ArticleIdList": ["10.1002/jcp.28349", "30790283"]}, {"Citation": "Montagut C., Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009;283:125\u2013134. doi: 10.1016/j.canlet.2009.01.022.", "ArticleIdList": ["10.1016/j.canlet.2009.01.022", "19217204"]}, {"Citation": "Luo J., Manning B.D., Cantley L.C. Targeting the pi3k-akt pathway in human cancer: Rationale and promise. Cancer Cell. 2003;4:257\u2013262. doi: 10.1016/S1535-6108(03)00248-4.", "ArticleIdList": ["10.1016/S1535-6108(03)00248-4", "14585353"]}, {"Citation": "Gelain A., Mori M., Meneghetti F., Villa S. Signal transducer and activator of transcription protein 3 (stat3): An update on its direct inhibitors as promising anticancer agents. Curr. Med. Chem. 2018 doi: 10.2174/0929867325666180719122729.", "ArticleIdList": ["10.2174/0929867325666180719122729", "30027840"]}, {"Citation": "Avalle L., Camporeale A., Camperi A., Poli V. Stat3 in cancer: A double edged sword. Cytokine. 2017;98:42\u201350. doi: 10.1016/j.cyto.2017.03.018.", "ArticleIdList": ["10.1016/j.cyto.2017.03.018", "28579221"]}, {"Citation": "Lee J.H., Kim C., Lee J., Um J.Y., Sethi G., Ahn K.S. Arctiin is a pharmacological inhibitor of stat3 phosphorylation at tyrosine 705 residue and potentiates bortezomib-induced apoptotic and anti-angiogenic effects in human multiple myeloma cells. Phytomedicine. 2018;55:282\u2013292. doi: 10.1016/j.phymed.2018.06.038.", "ArticleIdList": ["10.1016/j.phymed.2018.06.038", "30668440"]}, {"Citation": "Jung Y.Y., Shanmugam M.K., Narula A.S., Kim C., Lee J.H., Namjoshi O.A., Blough B.E., Sethi G., Ahn K.S. Oxymatrine attenuates tumor growth and deactivates stat5 signaling in a lung cancer xenograft model. Cancers. 2019;11 doi: 10.3390/cancers11010049.", "ArticleIdList": ["10.3390/cancers11010049", "PMC6356594", "30621055"]}, {"Citation": "Wu X.Y., Xu H., Wu Z.F., Chen C., Liu J.Y., Wu G.N., Yao X.Q., Liu F.K., Li G., Shen L. Formononetin, a novel fgfr2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget. 2015;6:44563\u201344578. doi: 10.18632/oncotarget.6310.", "ArticleIdList": ["10.18632/oncotarget.6310", "PMC4792576", "26575424"]}, {"Citation": "Baek S.H., Ko J.H., Lee J.H., Kim C., Lee H., Nam D., Lee J., Lee S.G., Yang W.M., Um J.Y., et al. Ginkgolic acid inhibits invasion and migration and tgf-beta-induced emt of lung cancer cells through pi3k/akt/mtor inactivation. J. Cell. Physiol. 2017;232:346\u2013354. doi: 10.1002/jcp.25426.", "ArticleIdList": ["10.1002/jcp.25426", "27177359"]}, {"Citation": "Mohan C.D., Srinivasa V., Rangappa S., Mervin L., Mohan S., Paricharak S., Baday S., Li F., Shanmugam M.K., Chinnathambi A., et al. Trisubstituted-imidazoles induce apoptosis in human breast cancer cells by targeting the oncogenic pi3k/akt/mtor signaling pathway. PLoS ONE. 2016;11:e0153155. doi: 10.1371/journal.pone.0153155.", "ArticleIdList": ["10.1371/journal.pone.0153155", "PMC4838272", "27097161"]}, {"Citation": "Singh S.S., Yap W.N., Arfuso F., Kar S., Wang C., Cai W., Dharmarajan A.M., Sethi G., Kumar A.P. Targeting the pi3k/akt signaling pathway in gastric carcinoma: A reality for personalized medicine? World J. Gastroenterol. 2015;21:12261\u201312273. doi: 10.3748/wjg.v21.i43.12261.", "ArticleIdList": ["10.3748/wjg.v21.i43.12261", "PMC4649111", "26604635"]}, {"Citation": "Siveen K.S., Ahn K.S., Ong T.H., Shanmugam M.K., Li F., Yap W.N., Kumar A.P., Fong C.W., Tergaonkar V., Hui K.M., et al. Y-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of akt/mTOR pathway in an orthotopic mouse model. Oncotarget. 2014;5:1897\u20131911. doi: 10.18632/oncotarget.1876.", "ArticleIdList": ["10.18632/oncotarget.1876", "PMC4039111", "24722367"]}, {"Citation": "Kim S.W., Kim S.M., Bae H., Nam D., Lee J.H., Lee S.G., Shim B.S., Kim S.H., Ahn K.S., Choi S.H., et al. Embelin inhibits growth and induces apoptosis through the suppression of akt/mtor/s6k1 signaling cascades. Prostate. 2013;73:296\u2013305. doi: 10.1002/pros.22574.", "ArticleIdList": ["10.1002/pros.22574", "22887478"]}, {"Citation": "Park K.R., Nam D., Yun H.M., Lee S.G., Jang H.J., Sethi G., Cho S.K., Ahn K.S. Beta-caryophyllene oxide inhibits growth and induces apoptosis through the suppression of pi3k/akt/mtor/s6k1 pathways and ros-mediated mapks activation. Cancer Lett. 2011;312:178\u2013188. doi: 10.1016/j.canlet.2011.08.001.", "ArticleIdList": ["10.1016/j.canlet.2011.08.001", "21924548"]}, {"Citation": "Lee J.H., Kim C., Lee S.G., Yang W.M., Um J.Y., Sethi G., Ahn K.S. Ophiopogonin d modulates multiple oncogenic signaling pathways, leading to suppression of proliferation and chemosensitization of human lung cancer cells. Phytomedicine. 2018;40:165\u2013175. doi: 10.1016/j.phymed.2018.01.002.", "ArticleIdList": ["10.1016/j.phymed.2018.01.002", "29496169"]}, {"Citation": "Ko J.H., Nam D., Um J.Y., Jung S.H., Sethi G., Ahn K.S. Bergamottin suppresses metastasis of lung cancer cells through abrogation of diverse oncogenic signaling cascades and epithelial-to-mesenchymal transition. Molecules. 2018;23:1601. doi: 10.3390/molecules23071601.", "ArticleIdList": ["10.3390/molecules23071601", "PMC6100248", "30004418"]}, {"Citation": "Lee H., Baek S.H., Lee J.H., Kim C., Ko J.H., Lee S.G., Chinnathambi A., Alharbi S.A., Yang W.M., Um J.Y., et al. Isorhynchophylline, a potent plant alkaloid, induces apoptotic and anti-metastatic effects in human hepatocellular carcinoma cells through the modulation of diverse cell signaling cascades. Int. J. Mol. Sci. 2017;18:1095. doi: 10.3390/ijms18051095.", "ArticleIdList": ["10.3390/ijms18051095", "PMC5455004", "28534824"]}, {"Citation": "Kannaiyan R., Manu K.A., Chen L., Li F., Rajendran P., Subramaniam A., Lam P., Kumar A.P., Sethi G. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-jun n-terminal kinase and suppression of pi3 k/akt signaling pathways. Apoptosis. 2011;16:1028\u20131041. doi: 10.1007/s10495-011-0629-6.", "ArticleIdList": ["10.1007/s10495-011-0629-6", "21786165"]}, {"Citation": "Sethi G., Ahn K.S., Sung B., Kunnumakkara A.B., Chaturvedi M.M., Aggarwal B.B. Sh-5, an akt inhibitor potentiates apoptosis and inhibits invasion through the suppression of anti-apoptotic, proliferative and metastatic gene products regulated by ikappabalpha kinase activation. Biochem. Pharmacol. 2008;76:1404\u20131416. doi: 10.1016/j.bcp.2008.05.023.", "ArticleIdList": ["10.1016/j.bcp.2008.05.023", "18606397"]}, {"Citation": "Ma X., Hu Y. Targeting pi3k/akt/mtor cascade: The medicinal potential, updated research highlights and challenges ahead. Curr. Med. Chem. 2013;20:2991\u20133010. doi: 10.2174/09298673113209990124.", "ArticleIdList": ["10.2174/09298673113209990124", "23651303"]}, {"Citation": "Dreher D., Junod A.F. Role of oxygen free radicals in cancer development. Eur. J. Cancer. 1996;32A:30\u201338. doi: 10.1016/0959-8049(95)00531-5.", "ArticleIdList": ["10.1016/0959-8049(95)00531-5", "8695238"]}, {"Citation": "Arora A., Nair M.G., Strasburg G.M. Antioxidant activities of isoflavones and their biological metabolites in a liposomal system. Arch. Biochem. Biophys. 1998;356:133\u2013141. doi: 10.1006/abbi.1998.0783.", "ArticleIdList": ["10.1006/abbi.1998.0783", "9705203"]}, {"Citation": "Kubota Y. Tumor angiogenesis and anti-angiogenic therapy. Keio J. Med. 2012;61:47\u201356. doi: 10.2302/kjm.61.47.", "ArticleIdList": ["10.2302/kjm.61.47", "22760023"]}, {"Citation": "Xiao L., Yang S., Hao J., Yuan X., Luo W., Jiang L., Hu Y., Fu Z., Zhang Y., Zou C. Endostar attenuates melanoma tumor growth via its interruption of b-fgf mediated angiogenesis. Cancer Lett. 2015;359:148\u2013154. doi: 10.1016/j.canlet.2015.01.012.", "ArticleIdList": ["10.1016/j.canlet.2015.01.012", "25597785"]}, {"Citation": "Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer. 2002;2:161\u2013174. doi: 10.1038/nrc745.", "ArticleIdList": ["10.1038/nrc745", "11990853"]}, {"Citation": "Li Y., Cheng H.S., Chng W.J., Tergaonkar V. Activation of mutant tert promoter by ras-erk signaling is a key step in malignant progression of braf-mutant human melanomas. Proc. Natl. Acad. Sci. USA. 2016;113:14402\u201314407. doi: 10.1073/pnas.1611106113.", "ArticleIdList": ["10.1073/pnas.1611106113", "PMC5167176", "27911794"]}, {"Citation": "Wang Y., Zhu Y., Gao L., Yin H., Xie Z., Wang D., Zhu Z., Han X. Formononetin attenuates il-1beta-induced apoptosis and NF-\u03baB activation in ins-1 cells. Molecules. 2012;17:10052\u201310064. doi: 10.3390/molecules170910052.", "ArticleIdList": ["10.3390/molecules170910052", "PMC6268495", "22922276"]}, {"Citation": "Duan P., Wang Z.M. Clinical study on effect of astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002;22:515\u2013517.", "ArticleIdList": ["12592686"]}, {"Citation": "Van den Bent M.J., Taphoorn M.J., Brandes A.A., Menten J., Stupp R., Frenay M., Chinot O., Kros J.M., van der Rijt C.C., Vecht Ch J., et al. Phase ii study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The european organization for research and treatment of cancer brain tumor group study 26971. J. Clin. Oncol. 2003;21:2525\u20132528. doi: 10.1200/JCO.2003.12.015.", "ArticleIdList": ["10.1200/JCO.2003.12.015", "12829671"]}, {"Citation": "Liu X., Fan D. The epithelial-mesenchymal transition and cancer stem cells: Functional and mechanistic links. Curr. Pharm. Des. 2015;21:1279\u20131291. doi: 10.2174/1381612821666141211115611.", "ArticleIdList": ["10.2174/1381612821666141211115611", "25506898"]}, {"Citation": "Su Y., Wang J., Zhang X., Shen J., Deng L., Liu Q., Li G. Targeting sim2-s decreases glioma cell invasion through mesenchymal--epithelial transition. J. Cell Biochem. 2014;115:1900\u20131907.", "ArticleIdList": ["24909296"]}, {"Citation": "Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009;119:1420\u20131428. doi: 10.1172/JCI39104.", "ArticleIdList": ["10.1172/JCI39104", "PMC2689101", "19487818"]}, {"Citation": "watsuki M., Mimori K., Yokobori T., Ishi H., Beppu T., Nakamori S., Baba H., Mori M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010;101:293\u2013299. doi: 10.1111/j.1349-7006.2009.01419.x.", "ArticleIdList": ["10.1111/j.1349-7006.2009.01419.x", "19961486"]}, {"Citation": "Ren J., Xu H.J., Cheng H., Xin W.Q., Chen X., Hu K. Synthesis and antitumor activity of formononetin nitrogen mustard derivatives. Eur. J. Med. Chem. 2012;54:175\u2013187. doi: 10.1016/j.ejmech.2012.04.039.", "ArticleIdList": ["10.1016/j.ejmech.2012.04.039", "22633834"]}, {"Citation": "Fu D.J., Zhang L., Song J., Mao R.W., Zhao R.H., Liu Y.C., Hou Y.H., Li J.H., Yang J.J., Jin C.Y., et al. Design and synthesis of formononetin-dithiocarbamate hybrids that inhibit growth and migration of pc-3 cells via mapk/wnt signaling pathways. Eur. J. Med. Chem. 2017;127:87\u201399. doi: 10.1016/j.ejmech.2016.12.027.", "ArticleIdList": ["10.1016/j.ejmech.2016.12.027", "PMC5567725", "28038329"]}, {"Citation": "Lin H.Y., Sun W.X., Zheng C.S., Han H.W., Wang X., Zhang Y.H., Qiu H.Y., Tang C.Y., Qi J.L., Lu G.H., et al. Synthesis, characterization and biological evaluation of formononetin derivatives as novel egfr inhibitors via inhibiting growth, migration and inducing apoptosis in breast cancer cell line. RSC Adv. 2017;7:48404\u201348419. doi: 10.1039/C7RA09825A.", "ArticleIdList": ["10.1039/C7RA09825A"]}, {"Citation": "Li Y.Q., Yang F., Wang L., Cao Z., Han T.J., Duan Z.A., Li Z., Zhao W.J. Phosphoramidate protides of five flavones and their antiproliferative activity against hepg2 and l-o2 cell lines. Eur. J. Med. Chem. 2016;112:196\u2013208. doi: 10.1016/j.ejmech.2016.02.012.", "ArticleIdList": ["10.1016/j.ejmech.2016.02.012", "26896708"]}, {"Citation": "Yang C., Xie Q., Zeng X., Tao N., Xu Y., Chen Y., Wang J., Zhang L. Novel hybrids of podophyllotoxin and formononetin inhibit the growth, migration and invasion of lung cancer cells. Bioorg. Chem. 2019;85:445\u2013454. doi: 10.1016/j.bioorg.2019.02.019.", "ArticleIdList": ["10.1016/j.bioorg.2019.02.019", "30776555"]}, {"Citation": "Guo B., Liao C., Liu X., Yi J. Preliminary study on conjugation of formononetin with multiwalled carbon nanotubes for inducing apoptosis via ros production in hela cells. Drug Des. Dev. Ther. 2018;12:2815\u20132826. doi: 10.2147/DDDT.S169767.", "ArticleIdList": ["10.2147/DDDT.S169767", "PMC6135071", "30233144"]}, {"Citation": "Mu H., Bai Y.H., Wang S.T., Zhu Z.M., Zhang Y.W. Research on antioxidant effects and estrogenic effect of formononetin from trifolium pratense (red clover) Phytomedicine. 2009;16:314\u2013319. doi: 10.1016/j.phymed.2008.07.005.", "ArticleIdList": ["10.1016/j.phymed.2008.07.005", "18757188"]}, {"Citation": "Barrera G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol. 2012;2012:137289. doi: 10.5402/2012/137289.", "ArticleIdList": ["10.5402/2012/137289", "PMC3483701", "23119185"]}, {"Citation": "Xing D.X., Liu X.L., Xue C.K., Huang Q., Liu Z.G., Xiong L. The estrogenic effect of formononetin and its effect on the expression of rats\u2019 atrium estrogen receptors. Zhong Yao Cai. 2010;33:1445\u20131449.", "ArticleIdList": ["21243777"]}, {"Citation": "Bertolini F., Marighetti P., Martin-Padura I., Mancuso P., Hu-Lowe D.D., Shaked Y., D\u2019Onofrio A. Anti-vegf and beyond: Shaping a new generation of anti-angiogenic therapies for cancer. Drug Discov. Today. 2011;16:1052\u20131060. doi: 10.1016/j.drudis.2011.08.007.", "ArticleIdList": ["10.1016/j.drudis.2011.08.007", "21875682"]}, {"Citation": "Hao Z., Sadek I. Sunitinib: The antiangiogenic effects and beyond. Oncol. Targets Ther. 2016;9:5495\u20135505. doi: 10.2147/OTT.S112242.", "ArticleIdList": ["10.2147/OTT.S112242", "PMC5021055", "27660467"]}, {"Citation": "Fei H.X., Zhang Y.B., Liu T., Zhang X.J., Wu S.L. Neuroprotective effect of formononetin in ameliorating learning and memory impairment in mouse model of alzheimer\u2019s disease. Biosci. Biotechnol. Biochem. 2018;82:57\u201364. doi: 10.1080/09168451.2017.1399788.", "ArticleIdList": ["10.1080/09168451.2017.1399788", "29191087"]}, {"Citation": "Jarred R.A., Keikha M., Dowling C., McPherson S.J., Clare A.M., Husband A.J., Pedersen J.S., Frydenberg M., Risbridger G.P. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol. Biomark. Prev. 2002;11:1689\u20131696.", "ArticleIdList": ["12496063"]}]}], "History": [{"Year": "2019", "Month": "3", "Day": "22"}, {"Year": "2019", "Month": "4", "Day": "22"}, {"Year": "2019", "Month": "4", "Day": "28"}, {"Year": "2019", "Month": "5", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "5", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "5", "Day": "6", "Hour": "6", "Minute": "1"}, {"Year": "2019", "Month": "5", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["31052435", "PMC6562434", "10.3390/cancers11050611", "cancers11050611"]}}]}